ALL patients with certain gene regulation patterns may be less likely to respond to CAR T-cell therapy

EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines

Patients treated with CAR T-cell medicines should be monitored life-long for secondary malignancies.

June 21, 2024

CAR T-cell therapy delivered to the brain shows clinical activity in glioblastoma in phase I study

A pioneering phase I CAR T-cell therapy trial for the treatment of glioblastoma at City of Hope, demonstrates promising clinical activity against incurable brain tumors, according to research published in Nature Medicine.

June 14, 2024

Vol.50 No.24

Drugs & Targets

Estonia to develop personalized CAR T-cell therapy for blood cancer patients

The Tartu University Hospital, North Estonia Medical Centre, and Icosagen have joined forces to develop and introduce an innovative personalized cell therapy for patients in Estonia.

May 31, 2024

Vol.50 No.22

Clinical Roundup

HER2-CAR T-cell therapy induces antitumor activity in high-risk sarcomas in phase I trial

Researchers at Texas Children’s Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital, and Houston Methodist published results of a phase I clinical trial of a novel immunotherapy for high-risk sarcomas on April 24 in Nature Cancer.

April 26, 2024

Vol.50 No.17

Clinical Roundup

Subgroup analysis focuses on P-BCMA-ALLO1 allogeneic CAR T in multiple myeloma

Data from a subset of patients in an ongoing phase I study of Poseida Therapeutics’s lead program P-BCMA-ALLO1 showed that three of the five (60%) patients with relapsed/refractory multiple myeloma who had progressed following BCMA-targeted therapy achieved clinical responses with P-BCMA-ALLO1. In addition, this investigational treatment was well-tolerated.

April 19, 2024

Vol.50 No.16

Drugs & Targets

FDA approves Abecma for earlier lines of treatment for MM

FDA approved Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, based on results from the KarMMa-3 trial (The Cancer Letter, March 22, 2024).

April 05, 2024

Vol.50 No.14

ALL patients with certain gene regulation patterns may be less likely to respond to CAR T-cell therapy

YOU MAY BE INTERESTED IN

EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines

CAR T-cell therapy delivered to the brain shows clinical activity in glioblastoma in phase I study

Estonia to develop personalized CAR T-cell therapy for blood cancer patients

HER2-CAR T-cell therapy induces antitumor activity in high-risk sarcomas in phase I trial

Subgroup analysis focuses on P-BCMA-ALLO1 allogeneic CAR T in multiple myeloma

FDA approves Abecma for earlier lines of treatment for MM

Renew today!

Subscriber content

Login